|
⚲
|
| Keyboard |
| The Column Group Management LP
✚
|
|
|---|---|
| CRD # | 161912 |
| SEC # | 802-76006 |
| CIK # | 0001645340, 0001833486 |
| AUM | |
| Employees | |
| Phone | 415-865-2050 |
| Address | One Letterman Drive San Francisco, CA 94129-1492 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Consonance-HFW Acquisition Corp | 55.8 | ||
| Oric Pharmaceuticals Inc | 44.9 | ||
| Revolution Medicines Inc | 0.0 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | The Column Group Opportunity IV LP | [2026-03-19] | 270.6 M | |
| Offered $600,000,000 · Filed 2025-12-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $600,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | The Column Group VI LP | [2026-03-19] | 270.6 M | |
| Offered $600,000,000 · Filed 2025-12-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $600,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | The Column Group - Neuro II LP | [2025-03-31] | 100.0 M | 98.5 M |
| Offered $100,000,000 · Filed 2024-02-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | The Column Group Opportunity III LP | [2023-03-17] | 600.0 M | 489.2 M |
| Offered $600,000,000 · Filed 2022-06-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | The Column Group SPV I LP | [2023-03-17] | 10.5 M | 10.3 M |
| Offered $10,543,500 · Filed 2022-12-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | The Column Group V LP | [2023-03-17] | 600.0 M | 533.5 M |
| Offered $600,000,000 · Filed 2022-06-16 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | The Column Group - Neuro LP | [2022-03-28] | 100.0 M | 93.1 M |
| Offered $100,000,000 · Filed 2021-05-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | The Column Group IVA LP | [2020-03-27] | 22.3 M | |
| Offered $25,000,000 · Filed 2019-12-11 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $25,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | The Column Group IV LP | [2020-03-27] | 730.1 M | |
| Offered $700,000,000 · Filed 2019-12-11 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $700,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Ponoi Capital II LP | [2019-03-29] | 81.6 M | |
| Offered $100,000,000 · Filed 2018-03-06 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $500,000 · Remaining $100,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Peter Svennilson | Executive Officer | 38 | 2 | |
| David Goeddel | Executive Officer | 38 | 2 | |
| Tim Kutzkey | Executive Officer | 27 | 2 | |
| Tim Kutzkey PhD | Executive Officer | 7 | 2 | |
| David Goeddel PhD | Executive Officer | 6 | 2 | |
| Magnus Persson MD PhD | Executive Officer | 2 | 2 | |
| David Goeddel Ph D | Executive Officer | 2 | 1 | |
| Harald Ekman | Executive Officer | 1 | 1 | |
| Richard Klausner MD | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001645340] | |
| 4 | [0001645340] | |
| 13F-HR | [0001833486] | |
| 4 | [0001833486] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
RAPT Therapeutics Inc RAPT
Common Stock
|
2024-12-23 | Other | 1,352,008 | ||
|
RAPT Therapeutics Inc RAPT
Warrant (right to purchase) · derivative
|
2024-12-23 | Other | 1,352,008 | ||
|
RAPT Therapeutics Inc RAPT
Warrant (right to purchase) · derivative
|
2024-12-23 | Other | 1,599,417 | ||
|
RAPT Therapeutics Inc RAPT
Common Stock
|
2024-12-23 | Other | 1,599,417 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 2,650,177 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 949,862 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Other | 1,000 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 1,298,908 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 1,298,908 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 100,000 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 100,000 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 15,000 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 44,000 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 2,265,758 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 11,103,333 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 858,035 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 968,990 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2024-04-05 | Disposed to issuer | 90,442 | ||
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2023-11-16 | Buy | 5,840 | $0.62 | 3,621 |
|
NGM Biopharmaceuticals Inc NGM
Common Stock
|
2023-11-15 | Buy | 16,791 | $0.71 | 11,922 |
| showing 20 of 200 most recent transactions | |||||